Contrasting Bolt Biotherapeutics (NASDAQ:BOLT) & Radiopharm Theranostics (NASDAQ:RADX)

Radiopharm Theranostics (NASDAQ:RADX) and Bolt Biotherapeutics (NASDAQ:BOLT) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, dividends, profitability, risk and earnings.

Earnings & Valuation

This table compares Radiopharm Theranostics and Bolt Biotherapeutics”s top-line revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Radiopharm Theranostics	$2.35 million	25.73	-$24.83 million	N/A	N/A
Bolt Biotherapeutics	$7.69 million	1.31	-$63.12 million	($22.38)	-0.23

Radiopharm Theranostics has higher earnings, but lower revenue than Bolt Biotherapeutics.

Insider & Institutional Ownership

86.7% of Bolt Biotherapeutics shares are held by institutional investors. 30.9% of Bolt Biotherapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of current recommendations for Radiopharm Theranostics and Bolt Biotherapeutics, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Radiopharm Theranostics	1	0	2	2	3.00
Bolt Biotherapeutics	1	2	2	0	2.20

Radiopharm Theranostics presently has a consensus price target of $15.33, indicating a potential upside of 199.48%. Bolt Biotherapeutics has a consensus price target of $34.00, indicating a potential upside of 547.62%. Given Bolt Biotherapeutics’ higher possible upside, analysts clearly believe Bolt Biotherapeutics is more favorable than Radiopharm Theranostics.

Profitability

This table compares Radiopharm Theranostics and Bolt Biotherapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Radiopharm Theranostics	N/A	N/A	N/A
Bolt Biotherapeutics	N/A	-94.22%	-50.56%

Summary

Radiopharm Theranostics beats Bolt Biotherapeutics on 6 of the 10 factors compared between the two stocks.

About Radiopharm Theranostics

Radiopharm Theranostics Ltd. operates as a pre-clinical and clinical research company. It focuses on the development of radiopharmaceutical products for diagnostic and therapeutic uses in areas of high unmet medical need. The company is headquartered Carlton, Australia.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer. It is also developing BDC-3042, an agonist antibody targeting Dectin-2 for range of tumors, such as head and neck, non-small cell lung, ovarian, triple-negative breast, and other cancer. The company has collaboration agreements with Toray Industries, Genmab A/S, Innovent Biologics, Inc., Bristol-Myers Squibb, and F. Hoffmann-La Roche Ltd; and license agreement with Stanford University. The company was formerly known as Bolt Therapeutics, Inc. and changed its name to Bolt Biotherapeutics, Inc. in July 2015. Bolt Biotherapeutics, Inc. was incorporated in 2015 and is headquartered in Redwood City, California.